Epizyme (EPZM) Upgraded at BidaskClub

Epizyme (NASDAQ:EPZM) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday.

Several other analysts have also weighed in on the company. Cann reissued a “buy” rating and set a $26.00 price objective on shares of Epizyme in a report on Tuesday, December 12th. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada downgraded Epizyme from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $20.00 to $16.00 in a research report on Thursday, November 2nd. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Epizyme in a research report on Thursday, November 2nd. Finally, ValuEngine downgraded Epizyme from a “hold” rating to a “sell” rating in a research report on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $22.60.

Shares of Epizyme (EPZM) opened at $16.60 on Thursday. Epizyme has a fifty-two week low of $9.30 and a fifty-two week high of $20.45. The firm has a market capitalization of $1,130.00, a P/E ratio of -7.31 and a beta of 2.00.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. equities research analysts anticipate that Epizyme will post -2.22 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jennison Associates LLC raised its position in Epizyme by 0.4% in the 4th quarter. Jennison Associates LLC now owns 1,875,528 shares of the biopharmaceutical company’s stock valued at $23,538,000 after purchasing an additional 7,867 shares during the last quarter. Peregrine Capital Management LLC bought a new position in Epizyme in the 4th quarter valued at $6,275,000. Fox Run Management L.L.C. raised its position in Epizyme by 64.7% in the 4th quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 7,575 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Epizyme by 13.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 245,756 shares of the biopharmaceutical company’s stock valued at $3,085,000 after purchasing an additional 28,588 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Epizyme in the 3rd quarter valued at $17,591,000. Hedge funds and other institutional investors own 85.29% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Epizyme (EPZM) Upgraded at BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/28/epizyme-epzm-upgraded-at-bidaskclub.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply